Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024

• 2024

  Sign in to bookmark this resource.

  Sign in
• Heidi Moline; Ariana Toepfer; Ayzsa Tannis; Geoffrey Weinberg; Mary Staat; Natasha Halasa
PMID: 39652359DOI: https://dx.doi.org/10.1001/jamapediatrics.2024.5572

---

Access Resources

• Journal ArticleEN

About

This study looks at the impact of respiratory syncytial virus (RSV) in young children during the 2023-2024 season. It describes how two new RSV prevention products, nirsevimab and Pfizer's maternal vaccine, were used to protect infants. The study compares RSV cases from 2017-2020 with those in 2023-2024 and finds similar hospitalization rates. Nirsevimab was found to be highly effective against RSV-related illnesses and hospitalizations. The research highlights the need for more widespread use of these prevention methods to reduce illness in children under five years old.

---

Tags

Hazard: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Antibodies, Monoclonal; Child, Preschool; Infant; Prospective Studies; Respiratory Syncytial Virus Infections; Respiratory Tract Infections

Institutions: Centers for Disease Control and Prevention (CDC); U.S. Public Health Service; University of Rochester; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Vanderbilt University; Texas Children's Hospital; Baylor College of Medicine; University of Washington; University of Pittsburgh; Children's Mercy Kansas City

---

More like this

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024 2024 · Centers for Disease Control and Prevention (CDC), Vanderbilt University, Seattle Children's Hospital, Baylor College of Medicine, University of Rochester Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2013 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---